Cost-effectiveness analysis of extended thromboprophylaxis with rivaroxaban versus no prophylaxis in high-risk patients after hospitalisation for COVID-19: an economic modelling study-Reference-Cited by-同舟云学术

Cost-effectiveness analysis of extended thromboprophylaxis with rivaroxaban versus no prophylaxis in high-risk patients after hospitalisation for COVID-19: an economic modelling study

Published:2023-08 Issue: Volume:24 Page:100543
ISSN:2667-193X
Container-title:The Lancet Regional Health - Americas
language:en
Short-container-title:The Lancet Regional Health - Americas

Author:

Carvalho de Oliveira Caroline Cândida,Agati Leandro Barile,Ribeiro Camilla Moreira,Resende Aguiar Valéria Cristina,Caffaro Roberto Augusto,da Silva Santos Marisa,Alves Fernandes Ricardo Ribeiro,Alberto da Silva Magliano Carlos,Tafur Alfonso,Spyropoulos Alex C.,Lopes Renato Delascio,Fareed Jawed,Ramacciotti Eduardo

Publisher

Elsevier BV

Subject

Public Health, Environmental and Occupational Health,Internal Medicine,Health Policy

Reference28 articles.

1. COVID-19 as the leading cause of hospital deaths in the Brazilian public health system in 2020;Zimmermann;Int J Infect Dis,2021

2. COVID-19 and cardiovascular disease;Clerkin;Circulation,2020

3. COVID-19 and the cardiovascular system;Zheng;Nat Rev Cardiol,2020

4. Factors associated with risk of postdischarge thrombosis in patients with COVID-19;Li;JAMA Netw Open,2021

5. Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry;Giannis;Blood,2021

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness of adjuvant endocrine treatment with tamoxifen for male breast cancer;Breast Cancer;2024-06-15

2. Long-term hypercoagulability, endotheliopathy and inflammation following acute SARS-CoV-2 infection;Expert Review of Hematology;2023-11-28